Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and 2023 Financial Results ROCKVILLE, MD., Mar 7, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023. "We expect that 2024 will be an important year f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, INC. (Exact name of registrant) Delaware 06-1591613 (State of organization) (I.R.S. Employer Identification Number ...

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Scott Koenig - President and Chief Executive Officer Jim Karrels - Senior Vice President and Chief Financial Officer Conference Call Participants Charles Zhu - Guggenheim Securities Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Jon Miller - Evercore Peter Lawson - Barclays Silvan Tuerkcan - JMP Securities Faisal Khurshid - Leerink Partners Stephen Willey - Stifel Operator Good afterno ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9704 Medical Center Drive Roc ...

MACRO GENICS® Corporate Update August 9, 2023 Cautionary Note on Forward-Looking Statements Legal Notices Trademarks Investigational Agents August 9, 2023 • Pursuing first-in-class targets 3 Multiple Platforms for Developing Innovative Biologics • Targeting improved efficacy and/or safety profile vs. traditional mAbs • Broad experience with CD3-directed bispecifics August 9, 2023 First-in-Human (Phase 1) Vobramitamab Duocarmazine (B7-H3) | --- | --- | --- | --- | --- | |--------------------------------|---- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpor ...

18 CONFIDENTIAL | --- | --- | |-------------------------------------|-------| | | | | Stratification Factors: | | | • Disease Location | | | (bone only vs. visceral) • Region | | PARCE SENICS MGD024 is investigational and has not yet been approved for marketing by any regulatory authority MACRO GENICS MGD024 MGD024: Favorable Cytokine Profile, Encouraging Combination Activity (in vivo) Improved Tolerability vs. Wild Type (WT) in Cynos 21 Preclinical data presented at ASH 2021 Interleukin-6 MGD024 Enhances A ...

MacroGenics, Inc. (NASDAQ:MGNX) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jim Karrels - Vice President, Chief Financial Officer Scott Koenig - President and CEO Conference Call Participants Jonathan Chang - SVB Securities Yigal Nochomovitz - Citi Kaveri Pohlman - BTIG Stephen Willey - Stifel Shay Simin - Barclays Operator Good afternoon. We will begin the MacroGenics 2023 First Quarter Corporate Progress and Financial Results Conference Call in just a moment. All participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpo ...

Developing Breakthrough Biologics, Life-changing Medicines® 2 DART, TRIDENT, MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc. All third-party trademarks used herein are registered trademarks of their respective owners. Integrated approach for exploiting direct and immune-based killing mechanisms Proof-of-Concept (Phase 2) Major Market Rights | --- | --- | --- | --- | --- | |--------------------------------|----------------------------------|-------- ...